In this engaging discussion, Dr. Nitin Jain interviews Dr. Hagop Kantarjian, a global pioneer in leukemia care, about groundbreaking advancements in leukemia and CML treatment over the past 40 years. Dr. Kantarjian reflected on the transformative milestones in leukemia care, including the evolution from intensive chemotherapy regimens to targeted therapies like BCR-ABL tyrosine kinase inhibitors, monoclonal antibodies, and chimeric antigen receptor (CAR)-T cell therapies. He highlighted breakthroughs such as the use of imatinib in chronical, myeloid leukemai (CML), which revolutionized survival outcomes in this group of patients.
Dr. Kantarjian also shareed his vision for a future with minimal chemotherapy, shorter treatment durations, and higher cure rates, leveraging molecular-targeted therapies and immune strategies.
